
Immunocore Holdings (IMCR) Stock Forecast & Price Target
Immunocore Holdings (IMCR) Analyst Ratings
Bulls say
Immunocore Holdings is supported by a strong commercial base in KIMMTRAK, which management says still shows no deterioration in underlying demand, with distributor inventory normalized and treatment duration holding at approximately 14 months, while the company estimates about 10% underlying revenue growth after normalizing for a $6.5 million stocking reversal and a prior-year extra selling week of about $5 million. Its pipeline adds meaningful upside: TEBE-AM has completed target enrollment in the 540-patient Phase 3 trial with overall-survival data now expected in 2Q27, and early brenetafusp combination data in metastatic uveal melanoma showed a 29% ORR, 24.1-month median response duration, and no grade ≥3 CRS, supporting a randomized Phase 2/3 DUET-UVEAL path. Beyond melanoma, IMC-P115C, IMC-S118AI, and IMC-U120AI broaden the platform’s long-term opportunity, while management’s continued investment across oncology, infectious disease, and autoimmune disease reinforces a diversified growth profile.
Bears say
Immunocore Holdings is facing a weaker fundamental outlook because the TEBE-AM readout shifted to 2Q27 after target enrollment was completed, delaying a key catalyst and pushing the timing of potential commercialization further out. That delay also forced a reset of launch assumptions, with U.S. KIMMTRAK in previously treated advanced cutaneous melanoma now modeled for 2028E and brenetafusp for 2030E, while 3Q26 KIMMTRAK revenue of $102.2 million missed estimates despite $901.3 million of cash, cash equivalents, and marketable securities. The company’s valuation is further pressured by a competitive backdrop, low 25% probability of success for brenetafusp, and risks around clinical execution, reimbursement, and dilution.
This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.
Immunocore Holdings (IMCR) Analyst Forecast & Price Prediction
Start investing in Immunocore Holdings (IMCR)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Immunocore Holdings (IMCR) Forecast
Immunocore Holdings (IMCR) Analyst Forecast & Price Prediction
Start investing in Immunocore Holdings (IMCR)
Order type
Buy in
Order amount
Est. shares
0 shares